Funding Biopharma Innovation
Strategies for investing in drug development and commercialization
Major breakthroughs in healthcare – from cell and gene therapies (CGT) to mRNA vaccines – have highlighted the power and value of investing in biopharma innovation. CGT alone could be worth US$80bn by 2029. However, in an industry where an estimated 90% of clinical drug development fails, biotech firms and start-ups need to stand out from the competition to appeal to investors looking for a solid return on investment.
There are deals to be done for biotech firms with the right therapeutic innovations. Big pharma companies are eyeing emerging start-ups as they seek to replenish their drugs pipeline before exclusivity rights on top-selling products expire. Investment firms are also looking to fill gaps in their portfolios. In the US, investor sentiment is improving because of a rebound in stock prices, expectations of a cut in interest rates and a boom in mergers and acquisitions in the sector. However, investors remain cautious about backing earlier stage and riskier companies.
The Financial Times, in partnership with Syneos Health, brought together investors, biotechs and big pharma for part two of the Funding Biopharma Innovation series. We explored how to create the competitive advantage that enables emerging biotechs to stand out from their peers. We shared insights into the innovative strategies being adopted by biotechs to increase the probability of successful drug development and commercial uptake; and how investors in biotechs are achieving positive returns.
Hear From Global Business Decision-Makers and Thought Leaders
Key discussion points
Securing capital to advance a biotech asset
What types of biotech innovations are exciting investors today?
Creating a strategy to maximize asset values
What are the benefits of establishing a market entry and commercialization strategy early on in development?
An investor’s perspective of the drug development pipeline
What are the trends for private equity investment in the pharma and biotech sector?
© Financial Times Live
FT Live and its journalism are subject to a self-regulation regime under the FT Editorial Code of Practice
